The consolidation nobody priced in

A market-size estimate is an opinion about the future. A 10-K is a sworn statement about the past. This piece stays with the second kind of number -- filed, IR-published, or registry-recorded -- and asks what it implies that the softer estimates in the companion piece66This piece is a companion to "Biomanufacturing's blurry number" (this site, /articles/biomanufacturing-since-2023, 2026-08-10), which covers the industry's market-size disagreement, 2025-2026 trends, and regulatory backdrop in full; this piece does not repeat that ground, only the company- and registry-level evidence beneath it.Primarythis site's own prior publication cannot.

What actually happened to the money

Samsung Biologics' own results, filed with its FY2025 earnings release, show revenue almost quadrupling in five years: KRW 1,165 billion in 2020 to KRW 4,557 billion in 2025.11Samsung Biologics. "Samsung Biologics Reports Fourth Quarter and Fiscal Year 2025 Financial Results." Samsung Biologics, January 21, 2026. Accessed August 10, 2026: FY2025 revenue KRW 4,557.0 billion (+30.3% YoY from KRW 3,497.1 billion), operating profit KRW 2,069.2 billion (+56.6% YoY).Primarycompany-reported consolidated results The operating margin moved with it, not against it -- 25.2% in 2020, 45.4% in 2025.77Samsung Biologics. "Annual Business Report." Samsung Biologics Investor Relations. Accessed August 10, 2026: consolidated K-IFRS income statement, revenue (operating profit) by year in KRW billion -- 2020: 1,165 (293); 2021: 1,568 (537); 2022: 2,437 (969); 2023: 2,939 (1,206); 2024: 3,497 (1,321); 2025: 4,557 (2,069). 2020-to-2022 revenue change: (2,437-1,165)/1,165 = 109%. 2022 figures include a newly consolidated US subsidiary and were unaudited per the company's own footnote.Primarycompany-reported consolidated financials That combination is the tell. A company scaling revenue on flat or thinning margins is selling more of the same thing at the same price. A company scaling revenue while margin nearly doubles is running fuller plants against a fixed cost base -- capacity utilization rising faster than capacity itself. Samsung's FY2025 revenue grew 30.3% year over year,11Samsung Biologics. "Samsung Biologics Reports Fourth Quarter and Fiscal Year 2025 Financial Results." Samsung Biologics, January 21, 2026. Accessed August 10, 2026: FY2025 revenue KRW 4,557.0 billion (+30.3% YoY from KRW 3,497.1 billion), operating profit KRW 2,069.2 billion (+56.6% YoY).Primarycompany-reported consolidated results a rate no whole-market CAGR estimate in the companion piece's eight-source range comes close to matching. Read plainly: the single biggest CDMO by capacity is compounding faster than the analysts who size the category it competes in.

Thermo Fisher's revenue tells a different, more honest story than either "growth" or "stagnation" -- it peaked at $44.9 billion in 2022, fell to $42.9 billion in both 2023 and 2024, and only in 2025 climbed back to $44.6 billion, still short of the 2022 high.22Thermo Fisher Scientific Inc. XBRL company-facts, tag RevenueFromContractWithCustomerExcludingAssessedTax. SEC EDGAR, CIK 0000097745. Retrieved August 10, 2026: FY2020 $32.2 billion, FY2021 $39.2 billion, FY2022 $44.9 billion, FY2023 $42.9 billion, FY2024 $42.9 billion, FY2025 $44.6 billion; FY2025 figure confirmed against the FY2025 10-K, filed February 26, 2026.Primaryfiled XBRL data and the underlying annual report The 2022 peak lines up with COVID-era diagnostics and vaccine-support revenue rolling off through 2023; the 2025 recovery is the first year that decline has reversed. Whether that recovery reflects genuine biomanufacturing demand or simple post-pandemic normalization is not established in this filing data alone -- but the direction, after two flat years, is now up.

Revenue and operating margin rising together, five years running -- filed and IR-reported figures, not an analyst's model.

The filing trail Catalent left behind

Catalent -- a name in the same top-five CDMO tier as Thermo Fisher and Samsung Biologics88Convergent 2026 CDMO rankings, cross-checked across multiple industry sources (see companion piece footnote for full listing): top tier Lonza, Samsung Biologics, WuXi Biologics, Catalent, Thermo Fisher (Patheon).Secondarysee companion piece for the full multi-source citation -- filed a 10-K as recently as September 2024, for its fiscal year ended June 30, 2024.99Catalent, Inc. Form 10-K for the fiscal year ended June 30, 2024. SEC EDGAR, filed September 6, 2024, accession 0001596783-24-000087.Primaryfiled annual report Three months later, on December 18, 2024, Novo Holdings completed its acquisition; the same day, Catalent filed a Form 25-NSE de-listing its shares from the New York Stock Exchange, and by December 30 had filed a Form 15-12G formally terminating its SEC reporting obligations.33Catalent, Inc. Form 8-K, "Introductory Note": "On December 18, 2024, Novo Holdings A/S ... completed the acquisition of Catalent, Inc. ... pursuant to the terms of the previously announced Agreement and Plan of Merger, dated as of February 5, 2024." SEC EDGAR, filed December 18, 2024, accession 0001193125-24-280922; deregistration confirmed by Form 15-12G, filed December 30, 2024.Primaryfiled merger-completion and deregistration documents

That is a company that, by its own paperwork, went from a routine annual filing to fully deregistered in sixteen weeks.99Catalent, Inc. Form 10-K for the fiscal year ended June 30, 2024. SEC EDGAR, filed September 6, 2024, accession 0001596783-24-000087.Primaryfiled annual report33Catalent, Inc. Form 8-K, "Introductory Note": "On December 18, 2024, Novo Holdings A/S ... completed the acquisition of Catalent, Inc. ... pursuant to the terms of the previously announced Agreement and Plan of Merger, dated as of February 5, 2024." SEC EDGAR, filed December 18, 2024, accession 0001193125-24-280922; deregistration confirmed by Form 15-12G, filed December 30, 2024.Primaryfiled merger-completion and deregistration documents Whether Novo Nordisk redirected any of Catalent's fill-finish capacity toward its own GLP-1 manufacturing is not established here -- but the timing is checkable and worth naming plainly: one of five named tier-one CDMOs disappeared as an independent filer in the same stretch that Thermo Fisher's revenue stopped falling and Samsung Biologics' margin hit a new high. Whether fewer independent competitors and rising margins at the survivors are connected, or simply concurrent, this document does not resolve. It is the kind of juxtaposition a market-size estimate, built from aggregated analyst inputs rather than named filings, cannot surface at all.

Thermo Fisher's filed revenue against Catalent's status as an independent SEC filer -- timing shown, not causation.

The demand side is already committed, not forecast

A market-size forecast is a guess about future spending. A registered clinical trial is a legal commitment already made. ClinicalTrials.gov shows 1,189 gene-therapy trials, 2,506 tagged cell-therapy, and 2,321 tagged CAR-T -- 259, 712, and 885 respectively still recruiting.44ClinicalTrials.gov, intervention-type searches for Gene Therapy and Cell Therapy. ClinicalTrials.gov and Cell Therapy search. Queried August 10, 2026: 1,189 gene-therapy trials (259 recruiting), 2,506 cell-therapy trials (712 recruiting), 2,321 CAR-T trials (885 recruiting); counts overlap and are not additive. Corrected in place: the first version of this piece reported 2,505 cell-therapy and 2,580 CAR-T from a mixed query form, which also produced the apparent oddity that CAR-T outnumbered its cell-therapy superset; run with one consistent quoted-phrase query the totals are 2,506 and 2,321 and the subset reads smaller than its superset, as it should.Primaryregistry data Treat these as an order-of-magnitude floor, not a precise sum: the counts overlap and are not additive, and their exact size depends on the query form -- with one consistent quoted-phrase query, cell therapy registers more studies than its nominal CAR-T subset, as it should.44ClinicalTrials.gov, intervention-type searches for Gene Therapy and Cell Therapy. ClinicalTrials.gov and Cell Therapy search. Queried August 10, 2026: 1,189 gene-therapy trials (259 recruiting), 2,506 cell-therapy trials (712 recruiting), 2,321 CAR-T trials (885 recruiting); counts overlap and are not additive. Corrected in place: the first version of this piece reported 2,505 cell-therapy and 2,580 CAR-T from a mixed query form, which also produced the apparent oddity that CAR-T outnumbered its cell-therapy superset; run with one consistent quoted-phrase query the totals are 2,506 and 2,321 and the subset reads smaller than its superset, as it should.Primaryregistry data Read narrowly, every one of these trials still represents a real demand claim on GMP viral-vector or cell-processing capacity that exists today or must exist within the trial's own timeline.

Total registered trials against the smaller slice actively recruiting now -- a floor under future manufacturing demand, not a ceiling.

Set this against the supply side above: one fewer independent tier-one CDMO, and the largest single CDMO running at a five-year-high margin. If margin expansion at Samsung Biologics reflects capacity running close to full, and Catalent's absorption removed one alternative from the market at the same time thousands of cell and gene trials are still recruiting toward eventual manufacturing needs, the setup is a demand curve that is not slowing meeting a supply side that just got one name shorter. This report does not have the data to say whether that gap is already binding -- but it has enough to say the gap is worth someone's attention before it does.

What the low end of the market estimate has to explain away

Put one filed number next to the companion piece's softest estimate and the low end gets hard to defend. Samsung Biologics' FY2025 revenue, KRW 4,557 billion, converts to roughly $3.2 billion at the prevailing rate of about 1,420 KRW per dollar.55USD/KRW exchange rate. Trading Economics. Accessed August 10, 2026: 1,425.14 (August 5, 2026 close); this piece uses approximately 1,420 as a round current-rate approximation for the FY2025 revenue conversion above -- a spot-rate translation, not the company's own reporting currency.Secondaryfinancial-data aggregator, for illustrative currency conversion only The lowest whole-market estimate in the companion piece's eight-source range is $19.08 billion.66This piece is a companion to "Biomanufacturing's blurry number" (this site, /articles/biomanufacturing-since-2023, 2026-08-10), which covers the industry's market-size disagreement, 2025-2026 trends, and regulatory backdrop in full; this piece does not repeat that ground, only the company- and registry-level evidence beneath it.Primarythis site's own prior publication One company -- a company that does nothing but contract biomanufacturing, unlike the diversified conglomerates in this tier -- would then already account for roughly one-sixth of the entire global market, before counting Lonza, WuXi Biologics, the newly Novo-owned Catalent, or Thermo Fisher's own biologics business.88Convergent 2026 CDMO rankings, cross-checked across multiple industry sources (see companion piece footnote for full listing): top tier Lonza, Samsung Biologics, WuXi Biologics, Catalent, Thermo Fisher (Patheon).Secondarysee companion piece for the full multi-source citation That arithmetic does not rule out a $19 billion market, but it requires the other four named tier-one CDMOs to collectively hold a noticeably smaller share than the single largest player -- a distribution the public rankings do not describe. The higher end of the range, $40.1 billion, leaves more room for five players of the scale these filings show. This is a back-of-envelope share check, not a market-sizing exercise of its own, and it does not apply to Thermo Fisher's $44.6 billion -- that figure is the whole company, not a biomanufacturing-specific segment, for the reason given above.

A convergence window, and a historical pattern worth watching rather than trusting

Three separate threads point at the same eighteen-month stretch. The FDA's Advanced Manufacturing Technologies Designation Program, finalized guidance December 2025, creates an actual regulatory fast lane for qualifying technology.1010US Food and Drug Administration. "Advanced Manufacturing Technologies Designation Program." FDA, final guidance December 2025, established under 21 U.S.C. Section 356l (FDORA 2022). Accessed August 10, 2026: designation triggers expedited review for drug applications manufactured using the designated technology.Primarysee companion piece for the full regulatory-backdrop discussion NIIMBL's Project Call 10.1 -- $8 million, concepts due September 9, 2026, with "Intelligent Biomanufacturing Through Artificial Intelligence, Digitalization, and Advanced Process Control" as the named lead topic -- funds the standards work underneath it.1111NIIMBL. "NIIMBL Announces Project Call 10.1 to Advance Biopharmaceutical Manufacturing Technology and Workforce Capabilities." NIIMBL, August 3, 2026. Accessed August 10, 2026: NIIMBL expects to launch a combined $8 million of project activities under Project Call 10.1; concept submissions due September 9, 2026, at 5pm ET; lead technical topic "Intelligent Biomanufacturing Through Artificial Intelligence, Digitalization, and Advanced Process Control."Primaryinstitute's own announcement And the patent-title data above shows the intellectual property being staked out in real time, not after the fact. None of these three is news alone. Together, they describe a regulator, a funding body, and inventors all moving on the same technology category in the same window -- which is the shape a category takes right before it becomes investable rather than experimental.

One historical parallel is worth naming and immediately discounting to its proper weight: the last time the federal government formally named "biomanufacturing" as its own category, in December 2016, patent filings using that exact word in the invention title went from essentially zero to a sustained 5-9 per year within about two years.1212US Patent and Trademark Office, Patent File Wrapper data, applications with "biomanufacturing" in the invention title. USPTO Patent Public Search. Queried August 10, 2026: 76 total matches; near-zero before 2015, then 5-9 filings per year from 2018 onward. Not classified by CPC code in this pass -- a title-text search only, flagged as a narrower proxy than a full field-wide patent count.Primarypatent office data, narrowly scoped1313US Department of Commerce / National Institute of Standards and Technology. "U.S. Secretary of Commerce Penny Pritzker Announces Biopharmaceutical Manufacturing Institute Joining Manufacturing USA Network." NIST, December 16, 2016. Accessed August 10, 2026: $70 million award establishing NIIMBL as the eleventh Manufacturing USA institute, the first with an industry-proposed focus area and the first funded directly by the Department of Commerce.Primaryfederal agency press release Whether "intelligent" or "AI-enabled" biomanufacturing follows the same naming-to-patenting lag is a pattern match from a single prior instance, not a forecast -- one data point is not a rule, and this report treats it as exactly that.

Where the next dollar of margin comes from

The workforce data in the companion piece -- 36% of facilities struggling to hire process-development staff -- reads differently next to Samsung Biologics' margin trajectory than it does alone.66This piece is a companion to "Biomanufacturing's blurry number" (this site, /articles/biomanufacturing-since-2023, 2026-08-10), which covers the industry's market-size disagreement, 2025-2026 trends, and regulatory backdrop in full; this piece does not repeat that ground, only the company- and registry-level evidence beneath it.Primarythis site's own prior publication A company that grows operating margin from 25% to 45% while its industry can't hire is not solving its capacity problem by adding people. NIIMBL's own funding priority names the alternative directly: automation, digitalization, and advanced process control, not headcount.1111NIIMBL. "NIIMBL Announces Project Call 10.1 to Advance Biopharmaceutical Manufacturing Technology and Workforce Capabilities." NIIMBL, August 3, 2026. Accessed August 10, 2026: NIIMBL expects to launch a combined $8 million of project activities under Project Call 10.1; concept submissions due September 9, 2026, at 5pm ET; lead technical topic "Intelligent Biomanufacturing Through Artificial Intelligence, Digitalization, and Advanced Process Control."Primaryinstitute's own announcement Read the two together and the implication is about where the marginal biomanufacturing dollar goes next -- toward the sensors, software, and closed-loop controls that raise output from plants already built, rather than toward the steel of new ones. This report does not have forward financial data to size that shift; it has enough to say the direction is consistent across every filing and funding signal it examined.

Where this sits in a longer arc

None of this is a new phenomenon so much as the latest turn of one. Biologics became their own manufacturing category in the 1980s, when recombinant insulin and the first monoclonal antibodies proved a living cell could be the factory.66This piece is a companion to "Biomanufacturing's blurry number" (this site, /articles/biomanufacturing-since-2023, 2026-08-10), which covers the industry's market-size disagreement, 2025-2026 trends, and regulatory backdrop in full; this piece does not repeat that ground, only the company- and registry-level evidence beneath it.Primarythis site's own prior publication The CDMO model that Lonza, Samsung Biologics, and Catalent all compete in today scaled through the 2000s, as sponsor companies without their own plants needed GMP capacity on demand.66This piece is a companion to "Biomanufacturing's blurry number" (this site, /articles/biomanufacturing-since-2023, 2026-08-10), which covers the industry's market-size disagreement, 2025-2026 trends, and regulatory backdrop in full; this piece does not repeat that ground, only the company- and registry-level evidence beneath it.Primarythis site's own prior publication COVID-19 forced a step-change in mRNA and cell-processing capacity that barely existed in 2019 -- Samsung Biologics' own 109% two-year revenue jump into 2022 traces it directly.77Samsung Biologics. "Annual Business Report." Samsung Biologics Investor Relations. Accessed August 10, 2026: consolidated K-IFRS income statement, revenue (operating profit) by year in KRW billion -- 2020: 1,165 (293); 2021: 1,568 (537); 2022: 2,437 (969); 2023: 2,939 (1,206); 2024: 3,497 (1,321); 2025: 4,557 (2,069). 2020-to-2022 revenue change: (2,437-1,165)/1,165 = 109%. 2022 figures include a newly consolidated US subsidiary and were unaudited per the company's own footnote.Primarycompany-reported consolidated financials And in December 2016, the US government treated biomanufacturing as a category worth its own federal institute for the first time -- NIIMBL, the eleventh Manufacturing USA institute and the first with a focus area industry itself had to propose rather than one Washington assigned.1313US Department of Commerce / National Institute of Standards and Technology. "U.S. Secretary of Commerce Penny Pritzker Announces Biopharmaceutical Manufacturing Institute Joining Manufacturing USA Network." NIST, December 16, 2016. Accessed August 10, 2026: $70 million award establishing NIIMBL as the eleventh Manufacturing USA institute, the first with an industry-proposed focus area and the first funded directly by the Department of Commerce.Primaryfederal agency press release

That last point closes a decade-long loop worth naming. In 2016, biomanufacturing needed industry to propose its own case for federal recognition as a category. A decade later, the FDA is actively promoting AI-enabled manufacturing and real-time release testing rather than merely tolerating it.1010US Food and Drug Administration. "Advanced Manufacturing Technologies Designation Program." FDA, final guidance December 2025, established under 21 U.S.C. Section 356l (FDORA 2022). Accessed August 10, 2026: designation triggers expedited review for drug applications manufactured using the designated technology.Primarysee companion piece for the full regulatory-backdrop discussion66This piece is a companion to "Biomanufacturing's blurry number" (this site, /articles/biomanufacturing-since-2023, 2026-08-10), which covers the industry's market-size disagreement, 2025-2026 trends, and regulatory backdrop in full; this piece does not repeat that ground, only the company- and registry-level evidence beneath it.Primarythis site's own prior publication The regulator went from absent to advocate in roughly the same window the industry went from fragmented to consolidating. A category that had to ask to be taken seriously now has its own designation program.

What this does not establish

This piece stays inside what filings, IR pages, and public registries say directly. It does not establish: whether Catalent's capacity was redirected and to where; whether Samsung Biologics' margin ceiling is near; whether the nearly 3,700 registered cell and gene trials will convert to manufacturing contracts at the rate their protocols assume; or a causal link between the consolidation and the margin trend, only their timing. The market-share arithmetic above is a spot-rate approximation, not an audited segmentation -- it argues the low end of the range needs a distribution the public rankings don't describe, not that any single figure is wrong. The naming-to-patenting pattern match rests on one prior instance and should be read as exactly that, not a rule. And the automation-over-headcount reading is a directional inference from two independently sourced trends, not a financial model of where capital actually flows next. A follow-up worth running once CPC-classified USPTO data or segment-level revenue becomes available: whether the patent-filing intensity behind "biomanufacturing" as an invention title tracks the same 2022-2025 window this piece covers.1212US Patent and Trademark Office, Patent File Wrapper data, applications with "biomanufacturing" in the invention title. USPTO Patent Public Search. Queried August 10, 2026: 76 total matches; near-zero before 2015, then 5-9 filings per year from 2018 onward. Not classified by CPC code in this pass -- a title-text search only, flagged as a narrower proxy than a full field-wide patent count.Primarypatent office data, narrowly scoped

---

Sources: SEC EDGAR (Thermo Fisher, Catalent), Samsung Biologics investor relations, ClinicalTrials.gov, NIST. Full raw query outputs -- SEC EDGAR XBRL company-facts, ClinicalTrials.gov results, USPTO patent-title data -- are archived alongside the companion piece's research files for independent re-derivation.

Footnotes

1. Samsung Biologics. "Samsung Biologics Reports Fourth Quarter and Fiscal Year 2025 Financial Results." Samsung Biologics, January 21, 2026. Accessed August 10, 2026: FY2025 revenue KRW 4,557.0 billion (+30.3% YoY from KRW 3,497.1 billion), operating profit KRW 2,069.2 billion (+56.6% YoY). (Primary -- company-reported consolidated results) ↩ ↩² ↩³ ↩⁴

2. Thermo Fisher Scientific Inc. XBRL company-facts, tag RevenueFromContractWithCustomerExcludingAssessedTax. SEC EDGAR, CIK 0000097745. Retrieved August 10, 2026: FY2020 $32.2 billion, FY2021 $39.2 billion, FY2022 $44.9 billion, FY2023 $42.9 billion, FY2024 $42.9 billion, FY2025 $44.6 billion; FY2025 figure confirmed against the FY2025 10-K, filed February 26, 2026. (Primary -- filed XBRL data and the underlying annual report) ↩ ↩²

3. Catalent, Inc. Form 8-K, "Introductory Note": "On December 18, 2024, Novo Holdings A/S ... completed the acquisition of Catalent, Inc. ... pursuant to the terms of the previously announced Agreement and Plan of Merger, dated as of February 5, 2024." SEC EDGAR, filed December 18, 2024, accession 0001193125-24-280922; deregistration confirmed by Form 15-12G, filed December 30, 2024. (Primary -- filed merger-completion and deregistration documents) ↩ ↩² ↩³

4. ClinicalTrials.gov, intervention-type searches for Gene Therapy and Cell Therapy. ClinicalTrials.gov and Cell Therapy search. Queried August 10, 2026: 1,189 gene-therapy trials (259 recruiting), 2,506 cell-therapy trials (712 recruiting), 2,321 CAR-T trials (885 recruiting); counts overlap and are not additive. Corrected in place: the first version of this piece reported 2,505 cell-therapy and 2,580 CAR-T from a mixed query form, which also produced the apparent oddity that CAR-T outnumbered its cell-therapy superset; run with one consistent quoted-phrase query the totals are 2,506 and 2,321 and the subset reads smaller than its superset, as it should. (Primary -- registry data) ↩ ↩² ↩³

5. USD/KRW exchange rate. Trading Economics. Accessed August 10, 2026: 1,425.14 (August 5, 2026 close); this piece uses approximately 1,420 as a round current-rate approximation for the FY2025 revenue conversion above -- a spot-rate translation, not the company's own reporting currency. (Secondary -- financial-data aggregator, for illustrative currency conversion only) ↩ ↩²

6. This piece is a companion to "Biomanufacturing's blurry number" (this site, /articles/biomanufacturing-since-2023, 2026-08-10), which covers the industry's market-size disagreement, 2025-2026 trends, and regulatory backdrop in full; this piece does not repeat that ground, only the company- and registry-level evidence beneath it. (Primary -- this site's own prior publication) ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

7. Samsung Biologics. "Annual Business Report." Samsung Biologics Investor Relations. Accessed August 10, 2026: consolidated K-IFRS income statement, revenue (operating profit) by year in KRW billion -- 2020: 1,165 (293); 2021: 1,568 (537); 2022: 2,437 (969); 2023: 2,939 (1,206); 2024: 3,497 (1,321); 2025: 4,557 (2,069). 2020-to-2022 revenue change: (2,437-1,165)/1,165 = 109%. 2022 figures include a newly consolidated US subsidiary and were unaudited per the company's own footnote. (Primary -- company-reported consolidated financials) ↩ ↩²

8. Convergent 2026 CDMO rankings, cross-checked across multiple industry sources (see companion piece footnote for full listing): top tier Lonza, Samsung Biologics, WuXi Biologics, Catalent, Thermo Fisher (Patheon). (Secondary -- see companion piece for the full multi-source citation) ↩ ↩²

9. Catalent, Inc. Form 10-K for the fiscal year ended June 30, 2024. SEC EDGAR, filed September 6, 2024, accession 0001596783-24-000087. (Primary -- filed annual report) ↩ ↩²

10. US Food and Drug Administration. "Advanced Manufacturing Technologies Designation Program." FDA, final guidance December 2025, established under 21 U.S.C. Section 356l (FDORA 2022). Accessed August 10, 2026: designation triggers expedited review for drug applications manufactured using the designated technology. (Primary -- see companion piece for the full regulatory-backdrop discussion) ↩ ↩²

11. NIIMBL. "NIIMBL Announces Project Call 10.1 to Advance Biopharmaceutical Manufacturing Technology and Workforce Capabilities." NIIMBL, August 3, 2026. Accessed August 10, 2026: NIIMBL expects to launch a combined $8 million of project activities under Project Call 10.1; concept submissions due September 9, 2026, at 5pm ET; lead technical topic "Intelligent Biomanufacturing Through Artificial Intelligence, Digitalization, and Advanced Process Control." (Primary -- institute's own announcement) ↩ ↩²

12. US Patent and Trademark Office, Patent File Wrapper data, applications with "biomanufacturing" in the invention title. USPTO Patent Public Search. Queried August 10, 2026: 76 total matches; near-zero before 2015, then 5-9 filings per year from 2018 onward. Not classified by CPC code in this pass -- a title-text search only, flagged as a narrower proxy than a full field-wide patent count. (Primary -- patent office data, narrowly scoped) ↩ ↩²

13. US Department of Commerce / National Institute of Standards and Technology. "U.S. Secretary of Commerce Penny Pritzker Announces Biopharmaceutical Manufacturing Institute Joining Manufacturing USA Network." NIST, December 16, 2016. Accessed August 10, 2026: $70 million award establishing NIIMBL as the eleventh Manufacturing USA institute, the first with an industry-proposed focus area and the first funded directly by the Department of Commerce. (Primary -- federal agency press release) ↩ ↩²